MEP1A

MEP1A encodes meprin-alpha, the alpha subunit of meprin A, a zinc metalloendopeptidase expressed predominantly in kidney and intestinal epithelia that functions as a cell-surface oligomeric protease involved in tissue remodeling and inflammatory regulation (PMID:7774936, PMID:10898933). MEP1A transcription is directly activated by CDX2 binding to its promoter and is suppressed by TNF-α through CDX2 downregulation, while its mRNA stability is negatively regulated by the lncRNA CCL14-AS (PMID:22326557, PMID:36793075). Loss of meprin-alpha exacerbates intestinal inflammation in DSS-colitis models, indicating a protective role in epithelial homeostasis, whereas in the cardiovascular system MEP1A promotes pathological remodeling: it drives cardiac hypertrophy and fibrosis via ERK1/2 activation, mediates mast-cell TNF-α secretion leading to smooth muscle cell apoptosis and abdominal aortic aneurysm, and enhances atherosclerotic lesion development through CXCL5 modulation and oxidative stress (PMID:19262505, PMID:33301800, PMID:32072633, PMID:34849841).

1. 1995 Medium

   Establishing that MEP1A encodes a distinct metalloendopeptidase subunit with an independent chromosomal locus resolved the structural identity of the human meprin-alpha gene and its relationship to MEP1B.

   Evidence Radiation hybrid and somatic cell hybrid mapping localized MEP1A to chromosome 6p11-p12

   PMID:7774936

   Open questions at the time

   • No enzymatic characterization of the recombinant human protein
   • Oligomeric assembly mechanism not addressed
   • Regulatory elements unknown
2. 2000 Medium

   Determining MEP1A gene structure and tissue expression revealed that the gene is restricted to kidney and intestinal tissues, providing the first framework for understanding its physiological context.

   Evidence Genomic cloning and dot blot analysis of poly(A) RNA from 50 human tissues

   PMID:10898933

   Open questions at the time

   • Protein-level tissue expression not confirmed
   • Promoter elements driving tissue specificity uncharacterized
   • Functional role in these tissues unknown
3. 2009 High

   Demonstrating that meprin-alpha deficiency worsens experimental colitis established a protective function for MEP1A in intestinal epithelial homeostasis, shifting the field from structural characterization to in vivo physiology.

   Evidence Meprin-alpha knockout mice subjected to DSS-induced colitis showed more severe injury and inflammation

   PMID:19262505

   Open questions at the time

   • Substrate(s) mediating the protective effect not identified
   • Downstream signaling pathway in intestinal epithelium unknown
   • Whether the protective role is cell-autonomous or paracrine not resolved
4. 2012 High

   Identifying CDX2 as a direct transcriptional activator of MEP1A and showing that TNF-α suppresses MEP1A through CDX2 downregulation linked inflammatory cytokine signaling to meprin-alpha regulation, providing a molecular explanation for reduced MEP1A in inflamed intestine.

   Evidence ChIP, reporter assays, and RT-PCR/immunoblotting in Caco-2 cells treated with TNF-α and infliximab

   PMID:22326557

   Open questions at the time

   • Whether other transcription factors co-regulate MEP1A not addressed
   • Mechanism by which TNF-α reduces CDX2 binding not fully dissected
   • In vivo validation of this transcriptional axis not performed
5. 2020 High

   Two studies revealed that MEP1A drives cardiovascular pathology through distinct cell-type-specific mechanisms — ERK1/2 activation in cardiac cells promoting hypertrophy/fibrosis, and mast-cell TNF-α secretion driving smooth muscle cell apoptosis and aortic aneurysm — demonstrating that MEP1A functions beyond the gut as a pro-inflammatory/remodeling protease in the vasculature and heart.

   Evidence Mep1a knockout and actinonin-treated mice with TAC/Ang II-induced cardiac hypertrophy and AAA models; in vitro cardiac myocyte, fibroblast, macrophage, and mast cell assays

   PMID:32072633 PMID:33301800

   Open questions at the time

   • Direct proteolytic substrates activating ERK1/2 or TNF-α release not identified
   • Structural basis for actinonin inhibition specificity not established
   • Mechanism linking meprin-alpha to TNF-α processing versus secretion unclear
6. 2021 High

   Showing that Mep1a deficiency in Apoe-null mice reduces atherosclerotic lesion size, necrosis, plasma CXCL5, and oxidative stress markers placed MEP1A as a pro-atherogenic factor and identified CXCL5 and oxidative stress as downstream effectors.

   Evidence Mep1a−/− Apoe−/− double knockout mouse model with lesion quantification and plasma biomarker analysis

   PMID:34849841

   Open questions at the time

   • Whether CXCL5 is a direct proteolytic substrate of meprin-alpha not tested
   • Cell type responsible for meprin-alpha action in lesions not resolved beyond expression data
   • Therapeutic potential of meprin-alpha inhibition in atherosclerosis not evaluated
7. 2023 Medium

   Discovery that the lncRNA CCL14-AS destabilizes MEP1A mRNA and that MEP1A overexpression rescues invasive phenotypes introduced a post-transcriptional regulatory layer and implicated MEP1A in colorectal cancer cell invasion.

   Evidence RNA interaction and mRNA stability assays, functional rescue experiments including lymph node metastasis in nude mice

   PMID:36793075

   Open questions at the time

   • Direct binding site of CCL14-AS on MEP1A mRNA not mapped
   • Mechanism by which MEP1A promotes invasion not identified
   • Single-study finding not independently confirmed

• The direct proteolytic substrates of meprin-alpha that mediate its in vivo effects in both intestinal protection and cardiovascular pathology remain unidentified, and structural determinants of its oligomeric assembly and substrate selectivity are unresolved.
• No substrate identified in any in vivo disease model
• Structural model of human meprin-alpha oligomer unavailable
• Opposing roles in gut (protective) versus vasculature (pathogenic) mechanistically unexplained